• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Neuropharmacology: Catecholamines
 

Neuropharmacology: Catecholamines

on

  • 678 views

Lecture 17 from a college level neuropharmacology course taught in the spring 2012 semester by Brian J. Piper, Ph.D. (psy391@gmail.com) at Willamette University.

Lecture 17 from a college level neuropharmacology course taught in the spring 2012 semester by Brian J. Piper, Ph.D. (psy391@gmail.com) at Willamette University.

Statistics

Views

Total Views
678
Views on SlideShare
678
Embed Views
0

Actions

Likes
0
Downloads
26
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Neuropharmacology: Catecholamines Neuropharmacology: Catecholamines Presentation Transcript

    • Neurochemistry of Catecholamines Brian J. Piper, Ph.D. Norepinephrine
    • Goals• Biosynthesis• Receptors• Neuroanatomy• Diseases• Drugs – L-Dopa – Methylphenidate
    • Definition• Catechol + amine (NH2) catechol• Members: – Dopamine – Norepinephrine (Noradrenaline) – Epinephrine (Nopepinephrine)
    • Precursor• Tyrosine: amino acid found in many foods including cheese & dairy products
    • Biosynthesis• Rate limiting (TH): controls production, found in axons
    • Biosynthesis• L-DOPA: L-3,4-dihydroxyphenylalanine
    • Parkinson’s Disease 1755-1824 • Progressive neurodegenerative disease • Described by James Parkinson in 1817 • Idiopathic (pesticides, genetics) • Prevalence: 3% of 65+ (500,000!) • Symptoms: resting tremor, pill rolling, slowness of movement • Tx: L-DOPA + peripheral AADC-I3 min: http://www.youtube.com/watch?v=ZHRT0uUo7Qs1 min: http://www.youtube.com/watch?v=_L_WF6gv5BI
    • Thanks, home chemists!• Barry Kidston develops Parkinson’s after synthesizing MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)• Later cases were described as: – “Three of the four patients were hospitalized with 14 days to 6 weeks of first use of the drug. Examination in each revealed near total immobility, marked generalized increase in tone, a complete inability to speak intelligibly, marked diminution of blinking, fixed stare, constant drooling” – Stopping L-DOPA resulted in “complete immobility & rigidity, being only able to move his eyes” Langston et al. (1983). Science, 219, 979-980.
    • MPTP= Parkinson’s model Immunocytochemistry for tyrosine hydroylase in rhesus monkeysParkinson’s Disease Normal Masilamoni et al. (2011). Brain, 134, 2057-2073.
    • Dopamine Release• VMAT2: vesiciular monoamine transporter, packages DA into vesicle• Dopamine Transporter (DAT): found on cell membrane, recycles dopamine• Receptor Families: – D1: – D2:
    • Dopamine Transmission• VMAT2: vesiciular monoamine transporter, packages DA into vesicle• DAT: Dopamine Transporter, found on cell membrane, recycles dopamine• Receptor Families: – D1: D1 & D5 – D2: D2 D3 D4
    • Dopamine Neuroanatomy 1 Mesocortical• Label: Soma-Axon Location, Mesencephalon-Cortex• Important for Schizophrenia
    • Dopamine Neuroanatomy 2 Mesolimbic• Limbic: amygdala, hippocampus, nucleus accumbens• Important for Drug-Abuse
    • Dopamine Neuroanatomy 3 Nigrostriatal• Nigro: substantia nigra• Striatum: caudate and putamen• Important for movement
    • Embryonic Transplants: An (Overly?)Optimistic Therapy
    • Dopaminergic DrugsDrug MechanismResperine VMAT inhibitor (irreversible)AMPT Inhibits tyrosine hydroxylase Rauvolfia serpentina6-OHDA Destroys DA (& NE) neurons (snakeroot)SCH 23390 D1 antagonistHaloperidol D2 antagonistCocaine Inhibits reuptake of DA (& NE)methylphenidate Inhibits reuptake of DA (& NE) Tyrosine hydroylase staining following 6-OHDA lesion of left-fibers of nigro- striatal pathway.
    • NorepinephrineSynthesis
    • Adrenergic Receptors• α : α1 α2• β : β1 β2
    • Functions of Norepinephrine
    • Catecholamine InactivationNET (norepinephrine transporter): membraneboundMAO (monoamine oxidase): found in neurons &gliaCOMT (catechol-O-methyl-transferase):intracellular & extracellular
    • ADHD Inattention• Symptoms present at school/work and home• 6+ symptoms that have persisted 6+ months and are inconsistent with developmental level – Often fails to give close attention or makes careless mistakes at school or at work. – Has difficulty sustaining attention in tasks or play. – Does not listen when spoken to directly. – Often does not follow through on instructions. – Has difficulty organizing activities. – Is easily distracted. – Is often forgetful in daily activities. 23
    • ADHD: Hyperactive-Impulsive• Symptoms present at school/work and home• 6+ symptoms that have persisted 6+ months and are inconsistent with developmental level – Often fidgets with hands or feet, leaves seat when staying seated is expected, runs or climbs excessively – Often blurts answer before ? completed – Has difficulty waiting turn – Often interrupts others 24
    • “Peculiar” Effects of Methylphenidate in Adolescents• Ritalin (Schedule II) is FDA approved for narcolepsy & ADHD• Pharmacological MRI was conducted in adolescent (PD35) and adult rats (PD 60+)Canese et al. (2009). Psychopharm, 203, 143-153.
    • Summary• Synthesis (TH, AADC)• Breakdown (DAT/NET, VMAT, MAO, COMT)• Receptors – D1 D2 –αβ
    • Is crystal methamphetamine the new crack? • Q) Is methamphetamine a national epidemic? • Q) Are there similarities between meth & crack? Dopamine Methamphetamine0-29:20http://www.justicetalking.org/ShowPage.aspx?ShowID=576